Specificity Study of Diagnostic for Early Detection of Dengue Infection
Launched by INBIOS INTERNATIONAL, INC. · Apr 7, 2014
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All age groups and both sexes.
- • Serum samples collected within 1- 7 days of onset of symptoms consistent with Dengue virus infection.
- • Information must be available about symptoms, age, and sex of patients from which samples are collected.
- Exclusion Criteria:
- • Any sample(s) with linked personal identifiers or any sample for which personal information can be discovered will be excluded.
About Inbios International, Inc.
Inbios International, Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative diagnostic solutions and therapeutics. With a strong focus on infectious diseases, Inbios leverages advanced technology and rigorous scientific research to create products that enhance disease detection and management. The company is committed to improving global health outcomes through its clinical trials and partnerships, ensuring that its solutions are safe, effective, and accessible to diverse populations. By prioritizing quality and compliance, Inbios International aims to be a leader in the diagnostic and therapeutic sectors, contributing to the advancement of healthcare worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jacksonville, Florida, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials